Company intelligence / Profile preview

Keren

Scarsdale, New York, United States

Ownership: Private
Development stage: Other

Overview

Keren Therapeutics is a biotechnology company dedicated to developing innovative treatments for sarcopenia and other age-related conditions. Founded by Dr. Hakim Djaballah, the company focuses on a naturally occurring peptide hormone, KT101, which is found in bone and dentin. Keren's therapeutic strategy involves using KT101 alone or in combination with selective androgen receptor modulators (SARMs) or myostatin inhibitors to address muscle fatigue and physical frailty. The company aims to improve the quality of life for the elderly by reversing or preventing muscle loss associated with aging.

Therapeutic areas: NeurologyOtherMetabolic Disorders
Modalities: PeptideSmall molecule
Industry: Biotech

Drug pipeline

3 assets

KT103

Preclinical

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Keren.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Keren.

Explore the full profile